Brief: InflaRx Submits Request For Emergency Use Authorization To US FDA
29/09/2022 14:26
Sept 29 (Reuters) - InflaRx NV IF0G.F :
* INFLARX SUBMITS REQUEST FOR EMERGENCY USE AUTHORIZATION TO
US
FDA FOR VILOBELIMAB FOR TREATMENT OF CRITICALLY ILL COVID-19
PATIENTS
* INFLARX NV SAYS EARNS FDA FAST TRACK DESIGNATION FOR
VILOBELIMAB
TO TREAT CRITICALLY ILL COVID-19 PATIENTS
* INFLARX NV SAYS EUA SUBMISSION FOR VILOBELIMAB, BASED ON
PHASE
III RESULTS IN CRITICALLY ILL COVID-19 PATIENTS
Source text for Eikon: ID:nGNXbzj6Px
Further company coverage: IF0G.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inflarx NV
See all newsBrief: Inflarx NV Files For Offerng Of Ordinary Shares, Size Not Disclosed - SEC Filing
Brief: InflaRx Reports Full Year 2025 Results And Highlights Key Achievements And Expected Milestones
Brief: Inflarx Announces Late-Breaker Oral Presentation On Vilobelimab Phase 3 Results In Pyoderma Gangrenosum At 2026 American Academy Of Dermatology Annual Meeting
Brief: Inflarx NV Executing 30% Workforce Reduction
Brief: Inflarx Provides Update On Phase 3 Data Analyses For Vilobelimab In Pyoderma Gangrenosum